Comparative structural and functional studies of 4-(thiazol-5-yl)-2- (phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity

Journal of Medicinal Chemistry

Volumn 56, Issue 3, 2013, Pages 660-670

  Hole, Alison J ^a,e   Baumli, Sonja ^a,e   Shao, Hao ^b   Shi, Shenhua ^b   Huang, Shiliang ^b   Pepper, Chris ^c   Fischer, Peter M ^b   Wang, Shudong ^b,d   Endicott, Jane A ^a,e   Noble, Martin E ^a,e  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(3 HYDROXYPHENYL)AMINO] 4 [4 METHYL 2 (METHYLAMINO)THIAZOL 5 YL]PYRIMIDINE 5 CARBONITRILE; 2 [(4 HYDROXYPHENYL)AMINO] 4 [4 METHYL 2 (METHYLAMINO)THIAZOL 5 YL]PYRIMIDINE 5 CARBONITRILE; 4 [4 METHYL 2 (METHYLAMINO)THIAZOL 5 YL] 2 [[3 (MORPHOLINE 4 CARBONYL)PHENYL]AMINO]PYRIMIDINE 5 CARBONITRILE; 4 [4 METHYL 2 (METHYLAMINO)THIAZOL 5 YL] 2 [[4 (MORPHOLINOSULFONYL)PHENYL]AMINO]PYRIMIDINE 5 CARBONITRILE; 4 [4 METHYL 2 (METHYLAMINO)THIAZOL 5 YL] 2 [[4 METHYL 3 (MORPHOLINOSULFONYL)PHENYL]AMINO]PYRIMIDINE 5 CARBONITRILE; 4 [[5 CYANO 4 [4 METHYL 2 (METHYLAMINO)THIAZOL 5 YL]PYRIMIDIN 2 YL]AMINO]BENZENESULFONAMIDE; 5,6 DICHLOROBENZIMIDAZOLE RIBOSIDE; CYANIDE; CYCLIN A; CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN T; N METHYL 5 [2 [[4 METHYL 3 (MORPHOLINOSULFONYL)PHENYL]AMINO]PYRIMIDIN 4 YL] 4 PHENYLTHIAZOL 2 AMINE; POSITIVE TRANSCRIPTION ELONGATION FACTOR B; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CRYSTAL STRUCTURE; DRUG CONFORMATION; DRUG POTENCY; DRUG SELECTIVITY; FLUOROMETRY; HYDROGEN BOND; MELTING POINT; PROTEIN DENATURATION; STRUCTURE ACTIVITY RELATION;

CYCLIN-DEPENDENT KINASE 9; HUMANS; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84873908358     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301495v     Document Type: Article

References (45)

1. Wang, S.; Fischer, P. M. Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology Trends Pharmacol. Sci. 2008, 29, 302-313
2. Peng, J.; Zhu, Y.; Milton, J. T.; Price, D. H. Identification of multiple cyclin subunits of human P-TEFb Genes Dev. 1998, 12, 755-762
3. Chao, S. H.; Fujinaga, K.; Marion, J. E.; Taube, R.; Sausville, E. A.; Senderowicz, A. M.; Peterlin, B. M.; Price, D. H. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication J. Biol. Chem. 2000, 275, 28345-28348
4. Marshall, N. F.; Price, D. H. Purification of P-TEFb, a transcription factor required for the transition into productive elongation J. Biol. Chem. 1995, 270, 12335-12338
5. Lam, L. T.; Pickeral, O. K.; Peng, A. C.; Rosenwald, A.; Hurt, E. M.; Giltnane, J. M.; Averett, L. M.; Zhao, H.; Davis, R. E.; Sathyamoorthy, M.; Wahl, L. M.; Harris, E. D.; Mikovits, J. A.; Monks, A. P.; Hollingshead, M. G.; Sausville, E. A.; Staudt, L. M. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol Genome Biol. 2001, 2, 0041.1-0041.11
6. Gojo, I.; Zhang, B.; Fenton, R. G. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1 Clin. Cancer Res. 2002, 8, 3527-3538
7. Raje, N.; Kumar, S.; Hideshima, T.; Roccaro, A.; Ishitsuka, K.; Yasui, H.; Shiraishi, N.; Chauhan, D.; Munshi, N. C.; Green, S. R.; Anderson, K. C. Seliciclib (CYC202 or R -roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma Blood 2005, 106, 1042-1047
8. Kim, K. S.; Kimball, S. D.; Misra, R. N.; Rawlins, D. B.; Hunt, J. T.; Xiao, H. Y.; Lu, S.; Qian, L.; Han, W. C.; Shan, W.; Mitt, T.; Cai, Z. W.; Poss, M. A.; Zhu, H.; Sack, J. S.; Tokarski, J. S.; Chang, C. Y.; Pavletich, N.; Kamath, A.; Humphreys, W. G.; Marathe, P.; Bursuker, I.; Kellar, K. A.; Roongta, U.; Batorsky, R.; Mulheron, J. G.; Bol, D.; Fairchild, C. R.; Lee, F. Y.; Webster, K. R. Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities J. Med. Chem. 2002, 45, 3905-3927
9. Joshi, K. S.; Rathos, M. J.; Joshi, R. D.; Sivakumar, M.; Mascarenhas, M.; Kamble, S.; Lal, B.; Sharma, S. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00 Mol. Cancer Ther. 2007, 6, 918-925
10. Chao, S. H.; Price, D. H. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo J. Biol. Chem. 2001, 276, 31793-31799
11. Zhou, Q.; Li, T.; Price, D. H. RNA polymerase II elongation control Annu. Rev. Biochem. 2012, 81, 119-143
12. Zuber, J.; Shi, J.; Wang, E.; Rappaport, A. R.; Herrmann, H.; Sison, E. A.; Magoon, D.; Qi, J.; Blatt, K.; Wunderlich, M.; Taylor, M. J.; Johns, C.; Chicas, A.; Mulloy, J. C.; Kogan, S. C.; Brown, P.; Valent, P.; Bradner, J. E.; Lowe, S. W.; Vakoc, C. R. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia Nature 2011, 478, 524-528
13. Delmore, J. E.; Issa, G. C.; Lemieux, M. E.; Rahl, P. B.; Shi, J.; Jacobs, H. M.; Kastritis, E.; Gilpatrick, T.; Paranal, R. M.; Qi, J.; Chesi, M.; Schinzel, A. C.; McKeown, M. R.; Heffernan, T. P.; Vakoc, C. R.; Bergsagel, P. L.; Ghobrial, I. M.; Richardson, P. G.; Young, R. A.; Hahn, W. C.; Anderson, K. C.; Kung, A. L.; Bradner, J. E.; Mitsiades, C. S. BET bromodomain inhibition as a therapeutic strategy to target c-Myc Cell 2011, 146, 904-917
14. Byrd, J. C.; Lin, T. S.; Dalton, J. T.; Wu, D.; Phelps, M. A.; Fischer, B.; Moran, M.; Blum, K. A.; Rovin, B.; Brooker-McEldowney, M.; Broering, S.; Schaaf, L. J.; Johnson, A. J.; Lucas, D. M.; Heerema, N. A.; Lozanski, G.; Young, D. C.; Suarez, J. R.; Colevas, A. D.; Grever, M. R. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia Blood 2007, 109, 399-404
15. Phelps, M. A.; Lin, T. S.; Johnson, A. J.; Hurh, E.; Rozewski, D. M.; Farley, K. L.; Wu, D.; Blum, K. A.; Fischer, B.; Mitchell, S. M.; Moran, M. E.; Brooker-McEldowney, M.; Heerema, N. A.; Jarjoura, D.; Schaaf, L. J.; Byrd, J. C.; Grever, M. R.; Dalton, J. T. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia Blood 2009, 113, 2637-2645
16. Lin, T. S.; Ruppert, A. S.; Johnson, A. J.; Fischer, B.; Heerema, N. A.; Andritsos, L. A.; Blum, K. A.; Flynn, J. M.; Jones, J. A.; Hu, W.; Moran, M. E.; Mitchell, S. M.; Smith, L. L.; Wagner, A. J.; Raymond, C. A.; Schaaf, L. J.; Phelps, M. A.; Villalona-Calero, M. A.; Grever, M. R.; Byrd, J. C. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease J. Clin. Oncol. 2009, 27, 6012-6018
17. Wang, S.; Wood, G.; Meades, C.; Griffiths, G.; Midgley, C.; McNae, I.; McInnes, C.; Anderson, S.; Jackson, W.; Mezna, M.; Yuill, R.; Walkinshaw, M.; Fischer, P. M. Synthesis and biological activity of 2-anilino-4-(1 H -pyrrol-3-yl) pyrimidine CDK inhibitors Bioorg. Med. Chem. Lett. 2004, 14, 4237-4240
18. Wu, S. Y.; McNae, I.; Kontopidis, G.; McClue, S. J.; McInnes, C.; Stewart, K. J.; Wang, S.; Zheleva, D. I.; Marriage, H.; Lane, D. P.; Taylor, P.; Fischer, P. M.; Walkinshaw, M. D. Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop Structure 2003, 11, 399-410
19. Wang, S.; Griffiths, G.; Midgley, C. A.; Barnett, A. L.; Cooper, M.; Grabarek, J.; Ingram, L.; Jackson, W.; Kontopidis, G.; McClue, S. J.; McInnes, C.; McLachlan, J.; Meades, C.; Mezna, M.; Stuart, I.; Thomas, M. P.; Zheleva, D. I.; Lane, D. P.; Jackson, R. C.; Glover, D. M.; Blake, D. G.; Fischer, P. M. Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents Chem. Biol. 2010, 17, 1111-1121
20. McIntyre, N. A.; McInnes, C.; Griffiths, G.; Barnett, A. L.; Kontopidis, G.; Slawin, A. M.; Jackson, W.; Thomas, M.; Zheleva, D. I.; Wang, S.; Blake, D. G.; Westwood, N. J.; Fischer, P. M. Design, synthesis, and evaluation of 2-methyl- and 2-amino- N -aryl-4,5-dihydrothiazolo[4,5- h ]quinazolin-8-amines as ring-constrained 2-anilino-4-(thiazol-5-yl)pyrimidine cyclin-dependent kinase inhibitors J. Med. Chem. 2010, 53, 2136-2145
21. Liu, X.; Shi, S.; Lam, F.; Pepper, C.; Fischer, P. M.; Wang, S. CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells when compared with flavopiridol Int. J. Cancer 2011, 130, 1216-1226
22. Shao, H.; Shi, S.; Huang, S.; Hole, A. J.; Abbas, A. Y.; Baumli, S.; Liu, X.; Lam, F.; Foely, D.; Fischer, P. M.; Noble, M. E. M.; Endicott, J. A.; Pepper, C.; Wang, S. J. Med. Chem., manuscript submitted. DOI: 10.1021/jm301475f.
23. Baumli, S.; Hole, A. J.; Wang, L. Z.; Noble, M. E.; Endicott, J. A. The CDK9 tail determines the reaction pathway of positive transcription elongation factor b Structure 2012, 20, 1788-1795
24. Fedorov, O.; Niesen, F. H.; Knapp, S. Kinase inhibitor selectivity profiling using differential scanning fluorimetry Methods Mol. Biol. 2012, 795, 109-118
25. Sehgal, P. B.; Derman, E.; Molloy, G. R.; Tamm, I.; Darnell, J. E. 5,6-Dichloro-1-beta- d -ribofuranosylbenzimidazole inhibits initiation of nuclear heterogeneous RNA chains in HeLa cells Science 1976, 194, 431-433
26. Bullock, A. N.; Debreczeni, J. E.; Fedorov, O. Y.; Nelson, A.; Marsden, B. D.; Knapp, S. Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase J. Med. Chem. 2005, 48, 7604-7614
27. Davies, T. G.; Bentley, J.; Arris, C. E.; Boyle, F. T.; Curtin, N. J.; Endicott, J. A.; Gibson, A. E.; Golding, B. T.; Griffin, R. J.; Hardcastle, I. R.; Jewsbury, P.; Johnson, L. N.; Mesguiche, V.; Newell, D. R.; Noble, M. E.; Tucker, J. A.; Wang, L.; Whitfield, H. J. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor Nat. Struct. Biol. 2002, 9, 745-749
28. Baumli, S.; Lolli, G.; Lowe, E. D.; Troiani, S.; Rusconi, L.; Bullock, A. N.; Debreczeni, J. E.; Knapp, S.; Johnson, L. N. The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation EMBO J. 2008, 27, 1907-1918
29. Baumli, S.; Endicott, J. A.; Johnson, L. N. Halogen bonds form the basis for selective P-TEFb inhibition by DRB Chem. Biol. 2010, 17, 931-936
30. Tahirov, T. H.; Babayeva, N. D.; Varzavand, K.; Cooper, J. J.; Sedore, S. C.; Price, D. H. Crystal structure of HIV-1 Tat complexed with human P-TEFb Nature 2010, 465, 747-751
31. Garbett, N. C.; Chaires, J. B. Thermodynamic studies for drug design and screening Expert Opin. Drug Discovery 2012, 7, 299-314
32. Romano, G.; Giordano, A. Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases Cell Cycle 2008, 7, 3664-3668
33. Cicenas, J.; Valius, M. The CDK inhibitors in cancer research and therapy J. Cancer Res. Clin. Oncol. 2011, 137, 1409-1418
34. Barrett, C. P.; Noble, M. E. Molecular motions of human cyclin-dependent kinase 2 J. Biol. Chem. 2005, 280, 13993-14005
35. Krystof, V.; Cankar, P.; Frysova, I.; Slouka, J.; Kontopidis, G.; Dzubak, P.; Hajduch, M.; Srovnal, J.; de Azevedo, W. F., Jr.; Orsag, M.; Paprskarova, M.; Rolcik, J.; Latr, A.; Fischer, P. M.; Strnad, M. 4-Aylazo-3,5-diamino-1 H -pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects J. Med. Chem. 2006, 49, 6500-6509
36. Baumli, S.; Hole, A. J.; Noble, M. E.; Endicott, J. A. The CDK9 C-helix exhibits conformational plasticity that may explain the selectivity of CAN508 ACS Chem. Biol. 2012, 7, 811-816
37. Brown, N. R.; Noble, M. E.; Endicott, J. A.; Johnson, L. N. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases Nat. Cell Biol. 1999, 1, 438-443
38. Leslie, A. G. W. Recent changes to the MOSFLM package for processing film and image plate data Jnt CCP4/ESF-EACBM Newsl. Protein Crystallogr. 1992, 26, 27-33
39. Kabsch, W. XDS Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 125-132
40. Collaborative computational project, number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. 1994, D50, 760-763
41. McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read, R. J. Phaser crystallographic software J. Appl. Crystallogr. 2007, 40, 658-674
42. Adams, P. D.; Afonine, P. V.; Bunkoczi, G.; Chen, V. B.; Davis, I. W.; Echols, N.; Headd, J. J.; Hung, L. W.; Kapral, G. J.; Grosse-Kunstleve, R. W.; McCoy, A. J.; Moriarty, N. W.; Oeffner, R.; Read, R. J.; Richardson, D. C.; Richardson, J. S.; Terwilliger, T. C.; Zwart, P. H. PHENIX: a comprehensive Python-based system for macromolecular structure solution Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 213-221
43. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53, 240-255
44. Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Features and development of Coot Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 486-501
45. Matulis, D.; Kranz, J. K.; Salemme, F. R.; Todd, M. J. Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using ThermoFluor Biochemistry 2005, 44, 5258-5266